Curasight‘s experimental cancer therapy, uTREAT, has successfully reached its target in the brain of the first patient dosed in a Phase 1 clinical trial.

The U.S. Food and Drug Administration (FDA) has granted its breakthrough therapy designation to sofetabart mipitecan as a potential treatment for people with platinum-resistant epithelial…

Treatment with Tecvayli (teclistamab) was better than standard therapies at delaying disease progression and prolonging survival among previously-treated myeloma patients in a Phase…